The use of narrow-band phototherapy with a wavelength of 311 nm in the treatment of patients with parapsoriasis

Abstract

Parapsoriasis is a heterogeneous group of chronic skin diseases, the clinical manifestations of which are inflammatory spots and/or papules and plaques covered with small lamellar scales. The relevance and medical and social importance of parapsoriasis is due not only to the permanent increase in the number of patients with this pathology, but also to the variety of clinical manifestations of the disease, the increase in severe aggressive course, errors in diagnosis and the lack of effective treatment methods. Objective — to study the effectiveness and safety of narrow-band phototherapy with a wavelength of 311 nm in the treatment of patients with parapsoriasis. Materials and methods. 16 patients with parapsoriasis were examined and treated, among whom large plaque was diagnosed in 4 (25 %), small plaque in 4 (25 %), lichenoid chronic in 5 (31.25 %), lichenoid and pustular acute parapsoriasis in 3 (18.75 %) patients. The age of the patients ranged from 19 to 53 years, there were 5 women (31.25 %), 11 men (68.75 %), the duration of the disease was from 6 months to 5 years. The treatment involved the appointment of patients with narrow-band phototherapy with a wavelength of 311 nm using the Dermalight 3000 phototherapy device (Dr. K. Hönle Medizintechnik GmbH, Germany). Results and discussion. The therapeutic effectiveness of the treatment was evaluated by the dynamics and degree of elimination of objective clinical manifestations and subjective signs of the disease, as well as by the long-term results of the treatment and the stability of remission. At the end of the course of treatment, clinical recovery was observed in 12 (75 %) patients, significant improvement in — 4 (25 %) patients. All patients underwent treatment without complications, side reactions and unwanted effects were not registered. Conclusions. Narrowband phototherapy with a wavelength of 311 nm is an effective and safe method of treating patients with parapsoriasis. Its use is possible both in inpatient and outpatient settings.